Corvus Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Corvus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 2 currently recruiting 6 completed early-phase tilt top decile by trial count

Corvus Pharmaceuticals: 10 sponsored US clinical trials, 2 recruiting.

Corvus Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 2 trials.

Top-decile sponsor footprint

Corvus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

NCT07441395
RECRUITING Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048
ACTIVE NOT RECRUITING Phase 1

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

NCT03952078
COMPLETED Phase 1

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

NCT06345404
TERMINATED Phase 3

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873
COMPLETED Phase 1

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

NCT04464395
COMPLETED Phase 1

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

NCT04280328
COMPLETED Phase 1

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

NCT03454451
COMPLETED Phase 1

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

NCT03237988
COMPLETED Phase 1

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1
Phase 3 2

Therapeutic Areas

Atopic Dermatitis 2
Eczema, Atopic 1
Lymphoma, T-Cell, Peripheral 1
Systemic Anaplastic Large Cell Lymphoma 1
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype 1
Follicular T-Cell Lymphoma 1
Angioimmunoblastic T-cell Lymphoma 1
Lymphoma, T-Cell 1
Peripheral T-Cell Lymphoma, Not Otherwise Specified 1
T-Cell Lymphoma 1

What is open in the Corvus Pharmaceuticals pipeline

2 recruiting of 10 indexed (20% open); 6 completed (60%).

Phase mix: 2 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Atopic Dermatitis (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Corvus Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 10 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

Corvus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%10%20%30%40% Total trials Recruiting share Corvus PharmaceuticalsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAcera SurgicalAlign TechnologyAltruBioAlvernia University
Corvus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Corvus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Corvus Pharmaceuticals page

10 registered trials is a research-attention snapshot, not an endorsement of Corvus Pharmaceuticals or any single study.

  • 2 of Corvus Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Atopic Dermatitis is the condition Corvus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Corvus Pharmaceuticals pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.